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ABSTRACT. 
 
Platelets for transfusion are stored at room temperature because refrigerated platelets  
are cleared rapidly from circulation. Room temperature storage causes major inconveniences 
for blood banks and medical risks for recipients. To address this clinically important problem 
a macrophage-dependent clearance mechanism was defined for platelets refrigerated < 4 h in 
buffer. Short-term platelet cooling (< 4 h) leads to exposure of !GlcNAc residues on GPIb". 
Exposed !GlcNAc are recognized by lectin domains on hepatic macrophages !M"2, which 
leads to increased clearance. Capping of exposed "GlcNAc by galactosylation using 
endogenous galactosyl transferases prevented clearance of short-term cooled platelets. In a 
follow up clinical study, galactosylation did not improve the circulation of human platelets 
stored in plasma at 4ºC for > 48 h (Paper 1). To investigate this different outcome we 
developed a mouse model for studies of storage of platelet-rich plasma (PRP) at 4°C for 48 h. 
In vitro characterization of the 4°C stored mouse platelets showed similar changes as 
measured on human platelets after 48 h of refrigeration. Importantly, using the mouse model 
we demonstrated that galactosylation has no effect on the survival of > 48 h long-term 
refrigerated mouse platelets (Paper 1). 
 
Using the mouse platelet storage model we dissected the clearance mechanism of platelets 
stored for > 48 h in plasma at 4ºC, showing that 48 h refrigerated platelets are removed by an 
additional macrophage-independent mechanism, i.e. by the hepatic galactose-dependent 
lectin the Ashwell-Morell Receptor (AMR) (Paper 2). This conclusion was based on the 
following evidence: (a) macrophage depletion in mice dramatically improved the circulation 
of 4 h chilled platelets, but not clearance of 48 h refrigerated platelets;  (b) streptavidin-POD 
staining revealed the localization of long-term refrigerated biotinylated platelets in 
hepatocytes; (c) 48 h refrigeration tremendously increased the binding of the "galactose-
recognizing lectin RCA-I to platelets; (d) KO mice lacking Asgpr-1 or Asgpr-2 subunits of 
the AMR supported 48 h refrigerated platelet circulation; (e)  co-injection of asialofetuin, a 
competitive inhibitor of the AMR, restored the survival of 48 h refrigerated platelets but not 
of isolated platelets stored for <4 h;  (f) ingestion of fluorescently labeled long-term 
refrigerated platelets in a hepatocyte culture was prevented by asialofetuin. Circulation of 48 
h platelets was markedly improved by removal of the N-terminal domain of GPIb! using O-
sialopeptidase (Paper 2).  
 
Platelets from mice lacking the sialyltransferase ST3GalIV were used to investigate the 
increased clearance of platelets with decreased sialylation. We demonstrated that platelets 
with increased galactose exposure due to the lack of ST3GalIV expression are also removed 
by a macrophage-independent mechanism, through AMRs on hepatocytes (Paper 3).  
 
In conclusion, our results defined a new hepatic-based clearance mechanism for desialylated 
platelets, representing the first example of blood cell removal by a non-myeloid cell. 
 
Keywords: platelet storage, Asialoglycoprotein receptor, GPIb" , "M!2, transfusion, 
clearance  
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ABBREVIATIONS. 
 
Ab   antibody  
" IIb!3  (GPIIb-IIIa, CD41/CD61) 
"M!2  (Mac-1, CR3, CD11b/CD18) 
Asgpr              Asialoglycoprotein receptor 
AMR  Ashwell-Morell receptor 
!-Gal               ! galactose 
!-GlcNAc  !-D-GlcNAc-1-Me, methylated !-N-acetylglucosamine  
CMTMR         5-(and-6)-(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine 
CMFDA  5-chloromethylfluorescein diacetate  
CRP  collagen related peptide 
C-T  carboxyl-terminal 
DMS  demarcation membrane system  
EM  electron microscopy 
FcR  Fc receptor  
FITC  fluorescein isothiocyanate 
GPIb"   glycoprotein Ib" 
GT  glycosyltransferase 
h  hours 
HepG2             hepatocellular carcinoma, human 
IP  immunoprecipitation 
ICAM  intercellular adhesion molecule  
ITAM  immunorecepor tyrosine-based activation motif  
KO  knock out 
LRR  leucine rich repeat 
Man                 mannose 
mAb  monoclonal antibody 
Min  minute 
MGL  macrophage galactose lectin  
N-T  amino-terminal 
OCS  open canalicular system 
POD                 peroxidase 
PAR  protease activated receptor  
PE  phycoerythrin 
PRP  platelet rich plasma 
PS  phosphatidyl serine 
RCA-I  ricinus communis agglutinin 
RT  room-temperature 
SR                    scavenger receptor 
s-WGA  succinylated wheat germ agglutinin  
THP-1 cells  human monocytic cell line 
TRAP  thrombin receptor activating peptide 
WT  wild-type 
vWf  von Willebrand factor 
vWfR  von Willebrand factor receptor, (GPIb",!/IX)2V 
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 INTRODUCTION TO THE PLATELET LIFE CYCLE. 
 
 
Fig. 1 Platelet lifespan. Platelets derive from precusor bone marrow megakaryocytes and are 
released as anuclear discs into the bloodstream. Upon injury or inflammation, platelet rolling is 
initiated by binding of GPIb! (the !-chain of the von Willebrand factor receptor complex) to von 
Willebrand factor (vWf) exposed on subendothelium. Further platelet adhesion and activation is 
mediated though GPVI binding to collagen, mediating platelet shape change, activation and 
granule release. Firm platelet adhesion is substantiated by !IIb"3-integrin binding to vWf and 
fibrinogen, inducing further platelet activation and thrombus formation. During their lifespan 
platelets fragment, lose terminal gycan residues such as sialic acids, and are eventually 
removed by macrophages and hepatocytes in the liver and spleen.  
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Platelets, anuclear discoid cell fragments that measure 2-4 µm in diameter, are released from 
megakaryocytes and circulate in blood as small discs with a half-life of 8-10 days in humans 
and 4-5 days in mice. Unequivocally, platelets are crucial for hemostasis and coagulation. 
Emerging literature increasingly suggests that platelets not only regulate hemostatic events 
but also play a substantial role in inflammation, metastasis and tumor growth. The following 
chapters will briefly address platelet birth, life and death (Fig. 1). 
 
Platelet birth. 
 
Megakaryocytes differentiate from hematopoietic stem cell precursor cells in the bone 
marrow [1-3]. The primary signal for megakaryocyte production and differentiation is 
thrombopoietin (TPO). TPO is sufficient but not necessary [4] for inducing differentiation of 
progenitor cells in the bone marrow towards a final megakaryocyte phenotype. Other 
molecular signals for megakaryocyte differentiation include GM-CSF, IL-3, IL-6, IL-11, 
chemokines (SDF-1; FGF-4) [5], and erythropoietin [6]. During their differentiation, 
megakaryocytes undergo endomitosis and become polyploid through repeated cycles of DNA 
replication without cell division [7]. The megakaryocyte cytoplasm continues to expand and 
the DNA complement can increase up to 64N.  
 
After the process of endomitosis is completed, the megakaryocyte begins a maturation stage 
in which the cytoplasm rapidly fills with platelet-specific proteins, organelles and membrane 
systems that will be ultimately subdivided and packaged into platelets. During the stage of 
maturation the megakaryocyte acquires its distinct ultrastructural features, including the 
development of a demarcation membrane system, the assembly of a dense tubular system, 
and the formation of granules [8]. However, the mechanisms by which megakaryocytes form 
and release platelets remain poorly understood. Interestingly, there is a remarkable contrast 
between the relative paucity of megakaryocytes in normal bone marrow and the relative 
abundance of platelets in peripheral blood. This contrast implies that platelet assembly and 
release processes are highly dynamic and efficient.  
 
The prevalent model for thrombopoiesis is the proplatelet model [2, 9],  which receives 
support mostly from megakaryocyte differentiation cultures [10, 11]. This model proposes 
that megakaryocytes extend plump pseudopodia that give rise to long (>100-#m) branched 
proplatelet processes that appear "beaded" by virtue of intermediate swellings [10-12]. It is 
unclear whether proplatelets detach from megakaryocytes in a bulk and fragment further into 
platelets [6], or whether barbell-shaped platelet pairs detach exclusively from proplatelet 
ends [12]. The second model is the platelet territory model which proposes that “platelet-
vesicles” form internally from demarcation membranes and are released as mature platelets 
into the blood stream [13, 14].  However, recently platelet production was observed in vivo, 
confirming the concept of proplatelet formation in vivo [15]. The investigators observed that 
megakaryocytes extended dynamic proplatelet-like protrusions into microvessels which 
appeared to be sheared from their trans-endothelial stems by flowing blood, resulting in the 
appearance of proplatelets in peripheral blood [15]. However, this observation remains 
purely descriptive and lacks insight into the mechanism of platelet formation. 
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Platelet life.  
 
Platelet dysfunction or low blood count predisposes to hemorrhage, while platelet hyper-
activation increases the risk of thrombosis. Once platelets are activated, they respond rapidly 
and in a sequential fashion to chemical and physical agents by changing shape, binding, 
spreading, secreting granules and aggregating to promote wound closure and healing [16, 
17]. The following section will briefly address the complex process of granule release and 
the function of major platelet receptors (Fig. 1). 
 
Platelet receptors.  
 
Platelet adhesion, activation and aggregation are mediated by specific surface receptors that 
include integrins, such as the fibrinogen receptor "IIb!3; the leucine-rich von Willebrand 
factor receptor, (GPIb",!/IX)2V; and the immunoglobulin-family receptors such as GPVI and 
P-selectin. The major glycoproteins in circulating platelets are the Willebrand factor receptor 
(vWfR) and the fibrinogen receptor "IIb!3 (GPIIb-IIIa or CD41/CD61) which interact with 
both soluble and tethered ligands to activate platelets [18].  
 
The ! IIb"3 integrin.  
 
Integrins are non-covalent heterodimers composed of "- and !-subunits that mediate cell-cell 
and cell-matrix interactions. "IIb!3 integrin is a calcium-dependent receptor for fibrinogen, 
and it is essential for platelet aggregation. "IIb!3 integrin expression is restricted to platelets 
and megakaryocytes. "IIb!3 has a very low affinity for fibrinogen on resting platelets [19]; 
however, after platelet activation, "IIb!3 receives signals from inside the cell to rapidly 
change its conformation to bind fibrinogen with high affinity. Its absence or deficiency leads 
to Glanzmann thrombocytopenia, a rare hematopoietic disorder associated with moderate to 
severe bleeding tendency and normal platelet morphology [18]. 
 
G-coupled receptors. 
 
Thrombin is a potent activator of platelets in vivo. When added to platelets in vitro, it causes 
phosphoinositide hydrolysis, which leads to an increase in intracellular Ca2+ concentration, 
shape change, granule release, and aggregation. Thrombin also suppresses cAMP synthesis in 
platelets by inhibiting adenylate cyclase [20]. All of these effects require that thrombin be 
proteolytically active. The PAR class of receptors has a distinctive mechanism of activation 
involving specific cleavage of the N-terminal extracellular domain. This exposes a new N-
terminus, which by refolding acts as a ligand to the receptor. The first human thrombin receptor 
to be identified was PAR-1 [21]. Subsequently, other PAR receptors, PAR-2[22], PAR-3 [23] 
and PAR-4 [24] have been identified. Mouse platelets express only PAR-3 and PAR-4 while 
human platelets express PAR- 1 and PAR-4, although PAR-1 appears to be the primary 
thrombin receptor on human platelets at low thrombin concentrations. The differential role of 
these receptors remains to be elucidated. 
 
P-selectin and PSGL-1. 
 
Selectins are cell adhesion molecules expressed on platelets, endothelial cells and 
lymphocytes. They belong to the C-type lectin family. There are three types of selectins: P-, 
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E- and L-selectins. Platelets and endothelial cells express P-selectin on the membrane of their 
"-granules and in Weibel-Palade bodies, respectively. P-selectin moves to the membrane 
surface during platelet and endothelial cell activation and plays an essential role in the initial 
recruitment of white blood cells to the site of injury during inflammation [25]. A well-
characterized ligand for P-selectin is PSGL-1, which is a mucin-type glycoprotein expressed 
on all white blood cells as well as on platelets [25, 26]. The affinity between the lectin-like 
domain of P-selectin and carbohydrate residues and sulfated tyrosines present on PSGL-1 
mediates the adhesion and rolling of white blood cells along the blood vessel wall and allows 
white blood cells to leave the blood vessel and enter the site of inflammation [27]. 
 
The von Willebrand factor receptor, (GPIb" ,!/IX)2V. 
 
The von Willebrand factor receptor, (GPIb",!/IX)2V, is a complex of 4 polypeptides: GPIb", 
GPIb!, GPIX and GPV [28-30] (Fig. 2). It belongs to the leucine-rich family of proteins and 
consists of four distinct transmembrane subunits: GPIb", connected to GPIb! by a disulfide 
bond, and the non-covalently associated GPIX and GPV. This receptor complex is present at 
~25,000-30,000 copies per platelet surface. In resting platelets, this highly glycosylated von 
Willebrand factor receptor (vWfR) complex is linked to underlying actin filaments by filamin 
A molecules [31]. The vWfR complex mediates activation and platelet adhesion to collagen-
bound vWf under high shear rates. Absence or deficiency of GPIb", GPIb! or GPIX is 
responsible for Bernard-Soulier Syndrome, a bleeding diathesis characterized by severe 
thrombocytopenia with abnormally large platelets and impaired platelet adhesion [32].  
Fig. 2 Von Willebrand factor receptor (vWfR) complex. The vWfR complex consists of four subunits 
GPIb", GPIb!, GPIX and  GPV. Filamin binds to the cytoplasmic tail of the GPIb" subunit and links the 
vWfR complex to actin cytoskeleton (F-actin). vWf binds to GPIb" under high shear stress and triggers 
activation of multiple signaling proteins. 
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The "-subunit, GPIb", is the best-described subunit of the vWfR. It is a type I membrane-
spanning subunit containing an external N-terminal, ligand-binding domain which includes 
leucine rich loops, an anionic peptide sequence with three tyrosine residues, a sialomucin 
core with multiple O-glycans, a transmembrane domain and a cytoplasmic tail (Fig. 3) [32]. 
  
Fig. 3  
Schematic diagram of the human von Willebrand factor receptor subunit GPIb"   
typical, complete N-glycan identified on GPIb" is shown (insert).  
 
 
O-sialo endopeptidase 
Mocarhagin 
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The extracellular N-terminal domain of GPIb" contains the binding site for vWf and 
interacts with various other ligands such as thrombin, platelet P-selectin, and 
neutrophil/macrophage !2 integrin "M!2 (Mac-1, CD11b/CD18) [32] [33], an integrin 
activated leukocytes use to adhere firmly to platelets. After vessel wall injury, platelet GPIb-
IX-V mediates the initial adhesion contact to vWf bound to collagen within the exposed 
vascular subendothelium under arterial shear rates, allowing platelets to roll at much slower 
velocities.  
 
The collagen receptor GPVI. 
 
GPVI is the major signaling receptor for collagen on the platelets [34, 35] and it is coupled to a 
disulfide-linked Fc receptor (FcR) #-chain homodimer in the membrane of human platelets 
[36]. Each FcR-chain contains one copy of the immunoreceptor tyrosine-based activation motif 
(ITAM) that undergoes tyrosine phosphorylation by Src family kinases upon crosslinking of 
GPVI. This leads to binding and activation of the tyrosine kinase Syk, and initiates 
downstream signaling events. PLC#2 is recognized as a central target for this signaling cascade 
[37].  
 
Platelet secretion. 
 
Platelets contain three major types of granules: "-granules, dense granules and lysosomes. 
Platelet secretion or exocytosis releases molecules at the site of injury to activate other cells 
or to facilitate cellular adhesion [38-40]. Platelets secrete molecules from intracellular 
granules.These molecules play central roles in hemostasis, thrombosis, and vascular 
remodeling [41-44].  
 
"-granules contain adhesive proteins such as vWf, fibrinogen, thrombospondin, and 
glycoprotein receptors such as the vWfR or the fibrinogen receptor "IIb!3 embedded in their 
membranes [45, 46]. Additionally, "-granules contain several growth factors, such as insulin-
like growth factor 1, platelet-derived growth factor TGF", platelet factor 4 (a heparin-binding 
chemokine) and the adhesion molecule P-selectin  [47-49]. Emerging literature documents 
that "-granules are packed differentially and that their molecular composition may come 
from different sources [50]. For example, vWf is primarily produced by megakaryocytes, 
while fibrinogen is believed to be endocytocytized from its surroundings during 
differentiation followed by packaging into "-granules [51, 52]. Granule secretion has been 
proposed to be regulated differentially [44], implying a highly regulated system of granule 
release. 
 
Dense granules are smaller than "-granules, serve as pools for intracellular calcium, and 
contain molecules such as adenine nucleotides (ADP and ATP), serotonin, histamin, and 
granulophysin [16, 17, 53]. Surprisingly, recent reports indicated that dense granules also 
contain proteins such as P-selectin, which were originally attributed to "-granules only [54]. 
This indicates that our current understanding of granule formation and status is only 
preliminary (Fig. 4). 
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Platelet death. 
 
Until recently, the only well-established mechanisms affecting platelet survival were 
antibody-mediated platelet clearance [55, 56], consumption of platelets by coagulation 
reactions, and loss due to massive bleeding. Clearance of senile platelets is believed to occur 
primarily in the spleen and liver and be mediated by macrophages. However, the signals 
regulating platelet clearance mechanisms are poorly understood. Platelets manipulated in 
vitro to express high levels of phosphatidylserine (PS) on their surfaces are rapidly ingested 
by macrophages in vitro [57]. Apoptotic mechanisms associated with senescent platelets lead 
to loss of mitochondrial membrane potential and subsequent distribution of phospholipids 
with increased phosphatidylserine exposure. However, it is unclear if those events are related 
to in vivo survival [58, 59]. In recent years, it has become increasingly apparent that the 
production of platelets and their subsequent life span in circulation are regulated, at least in 
part, by apoptotic mechanisms. The review by Kile et al. examines the role of the intrinsic 
apoptosis pathway, regulated by the Bcl-2 family of proteins in platelet biology [60].  
 
Platelet sizes are heterogeneous in blood. It has been postulated that size may be related to 
platelet age. In vivo data show that when platelet fragments are shed by megakaryocytes they 
certainly exceed normal platelet dimensions [15]. It is therefore likely that younger platelets 
are larger and are homeostatically more active because of their increased granule content [61-
63] [8]. While platelets circulate, their average platelet size and density declines [64], which 
presumably reflects the loss of membrane, granules and RNA [65, 66]. It is therefore possible 
Fig. 4  
Secretion. Upon activation, platelets undergo shape change and release dense and "-granule 
contents. 
 
 
"-granule contents: 
-Adhesion molecules  
(P-selectin,vWf,fibrinogen,"IIb!3) 
-Chemokines 
-Coagulation and fibrinolytic factors 
-Growth and angiogenesis factors 
-Immunologic molecules 
 
 
 
 
Dense granule contents: 
-Ions (Ca
2+
,Mg
2+
) 
-Nucleotides (ATP,GTP,ADP,GDP) 
-Coagulation and fibrinolytic factors 
-Membrane proteins (CD63) 
-Transmitters: Serotonin 
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that platelets are continuously “active/secretive” while circulating, shedding their plasma 
membrane components and granule contents to continuously promote vascular integrity and 
prevent bleeding, as consistently observed during thrombocytopenia. Such a process could 
contribute to the “aging/dying” process of circulating platelets. Whether such shedding plays 
a role in clearance is unknown, although conditions that lead to micro-vesiculation also lead 
to the activation of platelet calpain and promote the up-regulation of PS to the cell surface 
[8]. However, activation per se or platelet shape-change does not alter platelet survival [67-
69].  
 
Two additional phenomena were proposed to be associated with platelet aging: 1) sialic acid 
loss from terminal glycans [70] and 2) accumulation of IgG on platelet surfaces following the 
removal of sialic acid [71, 72]. However, the extent to which the two events contribute to 
platelet clearance has not been demonstrated.  
 
PLATELET STORAGE. 
 
The invention of platelet transfusions has allowed tremendous advancements in hematopoetic 
progenitor cell transplantations and chemotherapy, procedures often accompanied by severe 
thrombocytopenia and bleeding. However, therapeutic advances led to a disproportional 
demand for platelet transfusions [73] which perpetuated the demands on transfusion 
agencies. Improved platelet storage has permitted millions of transfusions per year, yet 
current blood banking practices for platelets are far from ideal. In 1969, Murphy and Gardner 
demonstrated that transfused human platelets stored at 4°C are rapidly cleared from 
circulation [74, 75]. They and others showed that platelets stored at room temperature (22°C) 
show significantly better recovery and survival, with a typical life span of 7-9 days versus 
only 2-4 days for refrigerated platelets [74, 75] [76, 77].  This odd phenomenon of chilled 
platelet clearance has had profound consequences for blood banking. For decades, all platelet 
products have been stored at room temperature, and because of the attendant risk of bacterial 
growth, platelet storage has been limited to five days.  
 
Refrigerated storage of platelet products would theoretically reduce the risk of bacterial 
growth [78, 79], permitting extended storage of platelets and bolstering product inventories. 
Competing technologies are now under development and might ultimately lessen the impact 
of these potential benefits [80]. For example, platelet bacterial testing may lead to the safe 
extension of room temperature storage of platelets [81]. Pathogen reduction technology could 
virtually eliminate not only bacteria, but viral and protozoal pathogens as well [82, 83]. 
Furthermore, improvements in platelet storage—such as second-generation storage 
containers with better O2/CO2 exchange and bigger platelet storage volumes—have stabilized 
pH values and resulted in better platelet viability [76, 84-86]. Storage of platelets in synthetic 
media (platelet additive solutions) may further reduce platelet metabolic rate and inhibit 
platelet activation during storage [87-89]. Although the usage of platelet additive solutions 
may be successful, this assessment is mostly based on in vitro studies. Only limited clinical 
evaluations have been published that either study the effectiveness of platelets in initially 
developed platelet additive solutions, or were specifically done in combination with pathogen 
reduction technologies. More clinical studies are needed to substantiate in vitro results before 
platelet additive solutions may safely replace plasma and allow extended storage with 
maintenance of quality [88, 90]. 
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Does platelet refrigeration offer any unique advantages? It is possible, although yet 
unproven, that 4°C storage could yield platelet products with clinically superior hemostatic 
function relative to their counterparts after extended storage at room temperature (i.e. > 5 
days).  
Platelet function: cold versus warm platelets. 
 
To be clinically effective, transfused platelets must (1) circulate and (2) function in clotting 
(i.e. prevent or stop bleeding). Currently, the gold standard test to evaluate platelet products 
is in vivo survival and count increment of transfused radiolabeled platelets [91, 92]. It is 
assumed that if a platelet product circulates normally, it should function appropriately. 
However, both parameters fail to assess the functional quality of transfused platelets. 
Furthermore, efficacy of a transfused platelet product is clearly patient-dependent, 
complicating the assessment of platelet functionality [93]. Unequivocally, clinical experience 
shows that platelet transfusions work. Improvements in treatment have rendered fatal 
hemorrhage considerably less common today, although thrombocytopenic patients receiving 
prophylactic transfusions in randomized platelet “trigger” trials have had clinically 
significant bleeding complications (WHO Grades 2-4) at rates of 17-21.5% irrespective of 
study arm [94, 95]. It seems therefore reasonable to question if higher functioning platelet 
products could reduce current bleeding rates. 
 
Platelets are metabolically active during room temperature storage, a factor that continuously 
diminishes platelet function. Metabolic products such as lactate accumulate during room 
temperature storage and precipitate a fall in pH [96]. pH levels below 6.0-6.2 have been 
associated with severely diminished platelet viability [92, 97-100]. In contrast, there is 
minimal lactate accumulation and no reduction in pH levels at 4°C [101, 102]. Platelets 
undoubtedly become activated during room temperature storage [103-107]. Key mediators of 
thrombosis stored in the "-granules of resting platelets, such as !-thromboglobulin and 
platelet factor 4, accumulate in the platelet storage medium over time [108]. Moreover, 
platelet surface P-selectin expression increases during room temperature storage [109], 
indicating that platelets continuously release their granule content, i.e. become activated.  
 
Whether cooling itself causes platelet activation is controversial. In many ways, platelets 
stored at 4°C seem to be less activated than platelets stored at room temperature.  For 
example, 4°C platelet storage does not lead to !-thromboglobulin release into the storage 
medium [108]. On the other hand, platelet chilling induces rapid, irreversible disc-to-sphere 
shape change [110]. Also, P-selectin exposure indicates "-granule content release [111-114]. 
P-selectin exposure had initially been suggested to accelerate platelet clearance [103, 105, 
113]; however, despite initial enthusiasm for the use of P-selectin as a marker of platelet 
quality in transfusion settings, P-selectin levels do not predict platelet survival after 
transfusion [67, 68, 105, 106]. Studies using platelets lacking P-selectin [68] or platelets 
activated with thrombin [67, 115] revealed that P-selectin exposure or loss of platelet discoid 
shape had no effect on platelet clearance. Conversely, spherical platelets characteristic in 
mice lacking !1-tubulin circulate normally [69, 112, 116]. Uncapping and fragmentation of 
actin filaments is one prerequisite for conversion of platelet discs to spheres following 
cooling [117]. However, preservation of discoid shape using actin-remodeling inhibitors did 
not diminish refrigerated platelet clearance [69, 112, 116]. Taken together, these studies 
show that preservation of platelet discoid shape does not predict platelet survival. 
 16 
Phosphatidyl serine exposure and loss of the vWfR complex "-chain (GPIb") following 
storage occur independent of the storage temperature [105, 111, 113, 118-121]. 
Unfortunately, it appears that as of today none of the measured surface markers reliably 
predicts platelet survival. 
 
It is assumed that both the retention of platelet discoid shape (as measured photometrically 
by the extent of shape change) and hypotonic shock response (indicating metabolic efficacy) 
report on platelet viability [96, 122-124]. Not surprisingly, platelets stored at room 
temperature perform better in both tests because platelets rapidly lose their “discoid shape” 
when chilled, implying that refrigerated platelets are not metabolically efficient and viable 
[75, 110, 124]. However, most investigators agree that 4ºC stored platelet products show 
better pH stability [101, 102], a reduced rate of glycolysis, and a better response when 
stimulated by ADP, epinephrine or collagen than do room temperature stored platelets [75, 
125]. These results imply that refrigerated platelets function better. 
 
In vivo studies of refrigerated human platelets. 
  
One key concept that has emerged from recent refrigerated platelet studies is that a platelet’s 
ability to survive normally in circulation may be entirely separable from its ability to function 
in blood clotting [112]. This concept challenges the “old” conclusion that refrigerated 
platelets are removed from the circulation because they do not function.  
 
A small number of human studies performed in the early 1970s suggest that platelets stored 
at 4°C have better in vivo function than room temperature platelets despite having poor 
survival in the circulation. Becker, Aster and colleagues [75] tested the effects of platelets 
refrigerated for $ 72 h in 68 thrombocytopenic patients. The patients, with pre-transfusion 
bleeding times of >15 minutes, were given fresh platelet concentrates, room temperature 
platelet concentrates that had been stored for 24, 48 or 72 hours, or 4°C platelet concentrates 
that had been stored for equivalent periods.  Bleeding times were measured one hour after 
transfusion. Platelets refrigerated for 48 or 72 hours corrected the bleeding time in 63% of 
cases, while room temperature platelets stored for an equivalent period corrected the bleeding 
time in only 24% of patients. In similar studies performed in aspirin-treated volunteers, 
bleeding times were corrected almost to baseline within four hours after transfusion with 4°C 
platelets.  In contrast, almost no effect was seen at this early timepoint in subjects receiving 
platelets stored at room temperature for 72 hours.  At 24 hours post-transfusion, substantial 
correction of the bleeding time was seen in the recipients of room temperature platelets [75] 
[77]. Another study showed that refrigerated ($ 72hrs) platelets transfused into 41 leukemia 
patients were clinically effective (i.e. stopped bleeding) and were considered “safe” in over 
100 transfused patients [126]. Similar observations were made by Handin and Valeri [127], 
who found that room temperature platelets corrected the bleeding time of aspirin treated 
volunteers 24 hours post-transfusion but had no effect immediately post-transfusion. 
Together, this evidence suggests that loss of in vitro platelet function may be reversible upon 
transfusion [127].  Based on these studies, the suggestion was made that platelets specifically 
intended to treat acute/active bleeding (i.e. trauma or surgical patients) should be stored at 
4°C, while platelets used for bleeding prophylaxis should be stored at room temperature 
[124, 128]. 
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However, this approach never gained acceptance, as studies performed subsequently failed to 
confirm that transfused room temperature platelets showed a significant delay in hemostatic 
function.  A study by Slichter and Harker showed that room temperature platelets 
consistently corrected the bleeding times of aplastic thrombocytopenic patients within 2
 
$ 
hours. In contrast, refrigerated (< 72 hours) platelets corrected the bleeding time in 6/8 cases 
shortly post-transfusion, but the effect was not sustained beyond 2 1/2
 
hours [76] [129]. Filip 
and Aster repeated the bleeding time experiments done previously in their laboratory [129] 
by administering either room temperature or 4°C platelets to 41 thrombocytopenic patients. 
They reported that platelets stored at room temperature for 24 hours produced the greatest 
bleeding time correction one hour post-
transfusion, while platelets stored at 4°C for 
72 hours yielded the least bleeding time 
correction, although the difference was not 
statistically significant.  The investigators 
attributed the relative ineffectiveness of 
room temperature platelets in their earlier 
study to inadequate (low) storage volume 
[76].  
 
The sole reason platelets are currently stored 
at room temperature is that chilled platelets 
do not circulate for an acceptable period of 
time in the recipient. It appears that the 
mechanisms dictating platelet removal from 
circulation, including for refrigerated 
platelets, are independent of platelet function 
and remain poorly understood. 
 
CLEARANCE MECHANISMS 
FOR REFRIGERATED 
PLATELETS: DUAL ROLES FOR 
HEPATIC LECTINS. 
 
Platelet glycobiology. 
 
Glycosylation is a posttranslational 
modification of proteins and lipids by 
attachment of oligoscharids through N- or O-linkage. Except for cytosolic O-GlcNAc 
glycosylation [130], glycosylation is confined to the endoplasmic reticulum and the Golgi 
apparatus. During modification, individual carbohydrate residues are added sequentially by 
glycosyltransferases. The synthesis of glycoconjugates is generally completed by addition of 
sialic acid or fucose which cap the structures and prevent further chain elongation (Fig. 5) 
[131]. Glycoconjugates without these terminal structures (also known as “immature” 
glycans) expose underlying incomplete carbohydrates such as "Galatose (!Gal) and 
"GlcNAc residues. Immature glycans are produced and presented on cell surfaces when their 
biosynthesis is affected, for instance in cancer cells. In contrast, the surface of normal 
mammalian cells is decorated with completed mature glycans. Glycans play essential roles in 
Fig. 5 Detection of exposed glycan residues 
using lectins. Sequential loss of terminal sialic 
acid or galactose residues exposes underlying 
galactose or !GlcNAc, respectively. Galactose or 
!GlcNAc residues are detectable with RCA-I or s-
WGA lectins, respectively. 
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cell-cell and cell-matrix interactions under physiological and pathophysiological conditions 
such as leukocyte trafficking and cancer metastasis [132].  
 
One of the major glycoproteins on the platelet surface is GPIb", which contains 60% of the 
total platelet glycan content, typically with up to four N-linked core-fucosylated glycans (two 
located within the N-terminus [133]) and O-linked glycans within the mucin rich region 
[134]. The glycans’ structures and their localization are indicated in Fig. 3. Normally, 
glycans on GP1b" are fully sialylated when completely assembled. However, upon 
refrigeration, loss of sialic acid exposes subterminal glycans such as !Gal or !GlcNAc.  Such 
residues are detectable by their binding to specific lectins, for example Ricinus communis 
agglutinin (RCA) I and succinylated wheat germ agglutinin (s-WGA) (Fig 5). GPIb" N-
terminal region and its N-linked carbohydrates have been implicated in the clearance of 
refrigerated platelets [135], [136]. However, it needs to be determined if GPIb" and it’s 
carbohydrate play a role in clearance of aging platelets in vivo. 
 
Lectin receptors. 
 
Lectins are sugar-binding proteins, highly specific for their sugar moieties. They typically 
play a role in biological recognition of cells and glycoproteins. Lectins have different 
biological functions ranging from regulation of cell adhesion to glycoprotein synthesis and 
the control of protein levels in the blood. In general it is believed that desialylated serum 
glycoproteins have drastically reduced survivals [137], a phenomenon originally 
demonstrated for desialylated ceruloplasmin [138, 139]. Resialylation significantly prolonged 
the survival of ceruloplasmin, pointing to the importance of sialic acid in preventing removal 
by !Gal recognizing receptors (Asgpr) [140]. The C-type lectin family consists of two 
galactose-recognizing receptors: the hepatic Ashwell-Morell receptor [141, 142] [143] and 
the macrophage scavenger receptor [144-146]. Both receptors show overlapping specificity 
and may function in parallel with each other [147, 148]. Unexpectedly, recent studies showed 
that Ashwell-Morell receptors not only recognize and clear desialylated proteins, but also 
mediate the clearance of sialic acid-deficient platelets [136, 149, 150]. Earlier, we 
demonstrated another unexpected macrophage-lectin based platelet clearance mechanism. 
We showed that the "M!2 integrin removes refrigerated platelets from the circulation by 
recognizing exposed !GlcNAc residues. Two major functions are attributed to "M!2 (or CR3, 
CD11b/CD18, MAC-1). First, it mediates adhesion and migration of leukocytes into 
inflammatory sites in tissues via binding to the intercellular adhesion molecule (ICAM-1) 
expressed on stimulated endothelium [151]. Second, "M!2 serves as a phagocytic receptor for 
the iC3b fragment of complement [152]. "M!2 also contains a cation-independent sugar-
binding lectin-site [153, 154] which either recognizes microbial surface polysaccharides or 
binds to GPI-linked signaling partners, thereby promoting phagocytosis of microbes [155]. 
That "M!2 and the Ashwell-Morell receptor mediate platelet clearance mechanisms is 
surprising and unexpected due to the size differences between platelets and proteins or 
bacteria. Whether the Ashwell-Morell receptor on hepatocytes or the "M!2 integrin are also 
involved in removal of senile platelets remains to be established. In the following paragraphs 
we will elucidate the fine interplay of two lectin receptors in the removal of sialic acid 
deficient platelets from the circulation.   
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Role of the macrophage !M"2-integrin in refrigerated platelet clearance.  
 
Earlier, we reported that the macrophage carbohydrate-binding !M"2 recognizes clustered 
GPIb! subunits of the vWfR complex following short-term refrigeration (2 h, 0°C), which 
results in the phagocytosis and clearance of platelets in vivo in mice and in vitro by human 
THP-1 macrophages [33, 112, 135, 156]. Experiments using !M"2-deficient mice [68] 
markedly improved the survival of refrigerated platelets. Removal of GPIb!’s ligand 
binding-domain using the O-sialoglycoprotein endopeptidase restored the circulation of 
refrigerated mouse wild-type platelets, which indicates that the external domain of GPIb! 
initiates clearance [112]. Subsequent work narrowed carbohydrate recognition by !M"2 to 
exposed "GlcNAc ("-N-acetylglucosamine) residues on N-linked GPIb! glycans (Fig. 3) 
[33, 135]. To remedy the poor circulation of refrigerated platelets a “capping strategy adding 
galactose residues to exposed "-GlcNAc residues” (galactosylation) was attempted. 
Surprisingly, both human and mouse platelets have functional platelet 
galactosyltransferase(s) on their surface. These enzyme(s) respond to the simple addition of 
UDP-galactose by transferring galactose onto exposed "GlcNAc residues of human or mouse 
GPIb! [135]. Galactosylation markedly improved the survival of mouse platelets refrigerated 
for 2 hours [135].  Galactosylation therefore provided a simple approach to improve 
refrigerated platelet circulation. 
 
While depriving the !M"2 lectin-domain of its "GlcNAc ligand on refrigerated platelets, 
galactosylation theoretically provides a new ligand for Asgprs. Hence, it was surprising that 
refrigerated mouse platelet circulation could be improved by galactosylation. It was 
postulated that the number of exposed "GlcNAc residues on GPIb! was small, such that 
even after clustering and galactosylation, the galactose density was insufficient to engage 
galactose-recognizing lectins [135].   
 
PAPER I. 
 
A clinical trial was performed using apheresis platelets refrigerated for 48 h. This phase-I 
clinical trial administered autologous, radiolabeled, galactosylated apheresis platelets 
refrigerated for 48 h into human volunteers. The results clearly showed that the 
galactosylation procedure did not extend their circulation time [119]. For logistical reasons, 
the early studies used isolated platelets and had not stored mouse platelets for clearance 
studies longer than hours. In contrast, platelets for transfusion were stored for days in platelet 
rich plasma. Consequently, the question arises if the mouse and human models differ and if 
prolonged platelet refrigeration led to a new clearance mechanism. We therefore developed a 
mini-bag methodology (Fig. 6) to support the storage of mouse platelet-rich plasma (PRP) at 
4ºC for up to 48 h. When mouse platelet-rich plasma was stored in mini-bags, a gradual loss 
of recoveries and survivals with longer storage times at 4°C was observed [119]. In vitro 
characterization of the 4°C stored mouse platelets demonstrated stable pH, but some increase 
in P-selectin exposure (18.1 ± 2.8 compared to 5.9 ± 1.4 % binding for fresh platelets) and 
moderate increase in annexin V binding (5.9±1.4 compared with 2.3 ±0.6 % binding for fresh 
platelets). Importantly, using a mouse transfusion system we subsequently found that just as 
with human platelets stored in plasma, galactosylation has no effect on the survival of > 48 h 
long-term refrigerated mouse platelets [119]. Furthermore, galactosylated mouse platelets 
stored for 48 hrs in plasma did not show improved circulation time when transfused into  
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"M!2 integrin deficient mice [119]. These results suggested that different mechanisms are 
involved in the clearance of platelets refrigerated for days.  
 
PAPER II. 
 
The role of the hepatic Asialoglycoprotein (Ashwell-Morell) receptor in refrigerated 
platelet clearance.  
 
Using the mouse transfusion model, we have dissected the clearance mechanism for platelets 
refrigerated for > 48 h in plasma.  We have found that as with short-term cooling, 
biotinylated or radiolabeled platelets refrigerated for 48 h in plasma (designated throughout 
the following text as long-term refrigerated platelets) are removed from the recipients’ 
circulation by the liver [136, 157] but, unexpectedly by hepatocytes [136]  and not by 
Kupffer cells (macrophages), as we previously reported for short-term cooled isolated 
platelets [112]. The in situ finding that hepatocytes can ingest long-term refrigerated platelets 
was confirmed using cultured hepatocyte cell lines (HepG2 cells) and human platelet 
concentrates refrigerated for up to 10 days. Further evidence that long-term refrigerated 
platelets are ingested by hepatocytes and not by macrophages was obtained by purging 
recipient mice of mature hepatic and splenic macrophages by injecting toxic clodronate-
encapsulated liposomes [158] prior to transfusions of fresh room temperature platelets or 
short- or long-term refrigerated and/or galactosylated platelets. As expected, removal of 
macrophages greatly improved recovery and survival of short-term cooled platelets, which 
confirmed our earlier results. In contrast, the recovery and survival of long-term refrigerated 
platelets were not affected by macrophage depletion, thus showing that removal of long-term 
refrigerated platelets is macrophage-independent and rather mediated by hepatocytes [136]. 
Interestingly, these studies also revealed that macrophages rapidly remove a large fraction of 
transfused fresh room temperature [136]. This result possibly reflects the detection of 
damage inflicted during isolation, consistent with a loss of ~30-40% platelet recovery that 
observed following the transfusion of fresh platelets into healthy volunteers [119].  
 
The Asialoglycoprotein (Ashwell-Morell) receptor. 
 
How does the hepatic galactose lectin or the Ashwell-Morell receptor recognize long-term 
refrigerated platelets? We reported that short-term cooled platelets have exposed/clustered 
!GlcNAc residues that are recognized and phagocytozed by the "M!2 hepatic macrophage 
receptors [112, 135]. In contrast, platelets refrigerated for long periods have severely 
increased galactose exposure, as evidenced by the galactose-binding lectins (RCA-I and 
ECA), which suggests a ligand for the hepatic Asiologycoprotein receptor. Consistent with 
this hypothesis, experiments using mice lacking Asgr-1 or Asgr-2 subunits of the Ashwell-
Morell receptor showed a significantly improved recovery and circulation of long-term 
refrigerated platelets. Similarly, co-injection of asialofetuin, a competitive inhibitor of the 
Ashwell-Morell receptor, restored the recovery and circulation of long-term refrigerated 
platelets, but not of short-term refrigerated platelets. Conversely, asialofetuin inhibited 
phagocytosis of human platelets refrigerated for up to 10 days by HepG2 cells in vitro [136]. 
Not surprisingly, long-term refrigerated and galactosylated platelets are cleared slightly faster 
independent of macrophage depletion [136]. Our studies, combined with a recent report by 
Grewal et al., point out the importance of a hepatic-based platelet removal system that uses 
the Ashwell-Morell receptor to recognize defectively sialylated proteins and remove platelets 
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which express desialylated glycans on their surface [149, 150] [136]. Whether hepatocytes 
also remove senile/desialylated platelets remains to be established. 
 
Desialylated glycans reside on GPIb"  following long-term refrigeration.  
 
We investigated whether GPIb" also plays a role in the removal of long-term refrigerated 
platelets, as we previously reported for short-term cooled platelets. Two of the putative N-
linked glycans are localized within the 45 kDa of GPIb" extracellular domain (Fig. 3) [133]. 
Removal of the N-terminal 282 residues of GPIb" from human platelets using the snake 
venom protease mocarhagin [159] or O-sialoglycoprotein endopeptidase eliminates two 
putative N-glycan residues, as well as the vWf-binding region of GPIb" [159]. Removal of 
GPIb"’s 45 kDa domain from mouse or human platelets significantly restored the circulation 
of long-term refrigerated wild-type mouse platelets and prevented human platelet ingestion 
by HepG2 cells in vitro, which indicates that most exposed !Gal and !GlcNAc residues 
reside within the external domain of GPIb" initiating clearance [136]. It is tempting to 
speculate that most of the exposed !Gal residues reside within N-linked glycans on GPIb", 
as shown previously for !GlcNAc [135]. However, it remains to be determined whether N-
linked glycans are solely involved in this interaction.  
 
Does GPIb" presentation influence platelet clearance? Platelets from ST3GalIV-/- mice have 
exposed galactose on surface glycoproteins as they lack "2-3-sialyltransferase activity [143, 
150].  In long-term refrigerated and rewarmed platelets, the mechanism of galactose exposure 
remains to be determined.  Release, or activation, of sialidase activity during storage could 
cleave terminal sialic acid residues, thus revealing underlying galactose residues. We 
observed increased clustering of GPIb" with prolonged refrigeration [136]. Hence, clustering 
of GPIb" subunits in the platelet with cooling might amplify the galactose signal and 
enhance lectin avidity and binding, as reported earlier for !GlcNAc [135]. However, the 
functional relationship between GPIb" clustering and platelet clearance by hepatocyte 
Ashwell-Morell remains to be established, particularly if proteolytic removal of GPIb"’s N-
Terminal 45 kDa portion alters clustering.  
 
Are glycoproteins other than GPIb" glycans involved in the clearance of cooled platelets? 
vWf binding increases with storage [136]. It appears that preferentially desialylated vWf 
binds to long-term refrigerated platelets, which indicates that desialylation of vWf molecules 
may promote binding to GPIb". In support of the notion that desialylated vWf binds better to 
platelets, we found that despite a 50% reduction of vWf concentration in ST3Gal-IV
-/-
 
plasma, binding of deficiently sialylated vWf to the vWfR on WT platelets is enhanced in 
vitro and in vivo [149]. Proteolytic removal of the GPIb" N-terminal region deprives GPIb" 
of its vWf-binding domain and binds less vWf. Whether vWf-glycans contribute to 
recognition of platelets by Ashwell-Morell receptor remains to be determined. 
 
PAPER III. 
 
Models for sialic acid deficient platelet uptake by hepatic Asialoglyocprotein receptor  
(Asgpr). 
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A number of specific sialyltransferase genes have been targeted in mice, and mice deficient 
in several of these enzymes exhibit defects in the hematopoietic cell lineage [160-162] . In 
particular, the ST3Gal-IV enzyme that transfers sialic acid in a !2,3 linkage to glycans with 
terminal Gal"1-4GlcNAc, Gal"1-3GlcNAc and Gal"1-3GalNAc sequences [163, 164] 
operates as a dominant modifier of hemostasis by concealing asialoglycoprotein ligands on 
platelets and vWf [160].   
 
The impact of deficient sialylation on platelet clearance following transfusion was tested 
using the ST3Gal-IV knock out mouse model with autosomal recessive thrombocytopenia. 
Platelets from ST3GalIV
-/-
 mice lack "2-3-sialyltransferase (ST3GalIV) activity [160], 
increasing exposure of penultimate "Gal on vWf and platelets and decreases plasma levels of 
these to 50% and 30% of normal values, respectively [160]. We have therefore used the 
ST3GalIV
-/-
 mice as a model to identify if ST3GalIV deficiency leads to similar platelet 
clearance mechanisms as found for long-term refrigerated platelets.  
 
In mice deficient in the ST3Gal-IV sialyltransferase gene we showed that thrombocytopenia 
is caused by the recognition of terminal galactose residues exposed on the platelet surface in 
the absence of sialylation. This results in accelerated clearance of transfused ST3Gal-IV
-/-
 
platelets by liver macrophages and hepatocytes [160], a mechanism that was recently shown 
to induce thrombocytopenia during S. pneumoniae sepsis [150]. We also identified platelet 
GPIb" as a major counter receptor on ST3Gal-IV-/- platelets for asialoglycoprotein receptors, 
as shown for long-term refrigerated platelets. Moreover, we reported that deficient sialylation 
increases vWf-mediated platelet activation and suggests that increased binding of deficiently 
sialylated vWf to platelets contributes to the accelerated clearance of ST3Gal-IV
-/-
 platelets. 
Taken together the data generated using ST3GalIV deficient mice and long-term refrigerated 
platelets establish the importance of sialylation for platelet clearance by hepatic lectins and 
vWf function. 
 
The Sections “Platelet storage” and “Clearance mechanisms for refrigerated platelets: Dual 
roles for hepatic lectins” will be published as a review article in Transfusion and Apheresis 
Science, December 2009. 
 
METHODS. 
 
Platelet preparation.  
 
Platelet isolation.  
 
Human and mouse platelets were obtained from whole blood, separated from
 
plasma and 
other cell components, washed, and resuspended at a concentration of 10
9
/mL
 
in 140 mM 
NaCl, 3 mM KCl, 0.5 mM MgCl2, 5 mM NaHCO3, 10 mM glucose,
 
and 10 mM Hepes, pH 
7.4 [112]. 
 
Platelet staining methods.  
 
Human and mouse platelets were labeled with 1.8 #M CellTracker
TM
 Orange CMTMR, or 
2.5 #M CellTracker Green CMFDA [165] for 20 min at 37 °C.  Unincorporated dye was 
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removed by centrifugation [112]. To study the fate of refrigerated platelets, isolated mouse 
platelets were biotinylated by incubation with 1 #g ml
-1
 Biotin-NHS for 1 h at RT. Unbound 
biotin was removed by centrifugation. Biotinylated or CMFDA labeled platelets were then 
resuspended in plasma and stored in mini-bags, as described below, before injection into 
mice [136]. 
 
Platelet temperature and storage protocols. 
 
To study the effects of cold on platelet survival and/or function, isolated platelets were 
incubated for 2 h at ice bath temperatures, a process designated as short-term cooling or as 
“0° C”, or resuspended in PPP and stored for 48 h at 4 °C (4° C), a process designated as 
long-term cooling or as “4° C”.  
In PAPER I a method for mouse platelet storage was developed. Mouse platelets
 
were 
injected into mini transfusion bags (0.9 mL/transfusion
 
bag) using a 27.5-gauge needle, 
sealed with a heat sealer (SEBRA,
 
Tucson, AZ), and placed in the dark for 6, 48, or 72 hours  
 
at
 
4°C without agitation or for 6 hours at room temperature
 
(22°C) on a horizontal table-top 
shaker rotating at 60 cycles/minute.
 
Platelet mini-bags (Fig. 6) with a storage volume of 1 mL 
to 2 mL were
 
made by heat-sealing 20-mm by 30-mm squares from gas-  
permeable
 
platelet storage bags (Gambro BCT, Lakewood, CO). All platelets stored in the 
cold were rewarmed for 15 minutes at 37 °C before use [119].  
In vivo platelet studies. 
Mouse platelet recovery, survival studies. 
To follow the fate of platelets stored at 0 °C, 4 °C or 22 °C , these platelets were injected into 
the retro-orbital venous plexus of syngeneic recipient mice. For recovery and survival 
determinations, blood samples were collected immediately (2 min), and at 5 min, 10 min, 0.5 
h, 2 h, 24 h, 48 h, and 72 h.  Platelet rich plasma (PRP) was isolated from whole blood and 
analyzed by flow cytometry (Becton Dickinson Biosciences) and the percentage of CMFDA 
positive platelets determined [165]. Biotinylated platelets were distinguished from 
Platelets obtained 
from whole blood and 
separated from PRP 
Isolated platelets 
stained with Orange 
CMTMR CellTracker 
Green CMFDA 
Isolated platelets 
labeled with biotin 
Biotinylated or CMFDA labeled 
platelets resuspended in plasma 
and stored in mini-bags 
Fig. 6 
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endogenous platelets by addition of Phycoerythrin (PE) conjugated Streptavidin (PE-
Streptavidin). PRP was incubated with PE-Streptavidin for 20 min at room temperature and 
the percentage of biotinylated platelets was determined by flow cytometry (Fig. 7). 
 
Mouse platelet fate.  
 
Immunohistology. 
 
 Mice were infused with 3x10
9
 of biotinylated platelets. Organs were collected at 5, 15, and 
30 min and 24 h and were formalin-fixed, embedded in paraffin, and sectioned every 3 #m. 
The distribution of biotin (biotinylated platelets) was visualized using Strepavidin-POD 
conjugate and ImmunoHisto
TM 
Peroxidase Detection Kit (PIERCE). Sections were 
counterstained with H&E according to the manufacturer’s recommendations. Quantitative 
analysis of staining was done in blinded samples. Ten tissue sections were selected from 
Mice were sacrificed 
and organs (liver, 
spleen, lung) were 
harvested 
Biotinylated platelets 
transfused into recipient 
mice 
Perfused organs  
formalin-fixed, 
embedded in paraffin, 
and sectioned 
Biotin (biotinylated 
platelets)  visualized 
using Strepavidin-
POD 
Fig. 8 
Fig. 7 PE-Streptavidin 
Blood samples 
were collected 
from mice 
transfused with 
labeled platelets 
CMFDA labeled 
platelets 
Biotinylated 
platelets 
Unlabeled 
platelets 
Unlabeled 
platelets 
PRP isolated from whole blood 
Biotinylated platelets  
detected by Streptavidin 
CMFDA labeled  
platelets 
Fluorescence 
Fluorescence 
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mice with similar levels of injected platelets and scored for hepatocytes and macrophages 
containing biotinylated platelets (Fig. 8).  
 
Radioactive labeled platelet fate.  
 
To evaluate the fate of platelets, tissues were harvested from recipient mice 1 h after the 
injection of 0.4 x 10
9 111
Indium-labeled (NEN Life Science Products) platelets. Platelets were 
radiolabeled after storage as described before [112].  Organ-weight was measured and 
radioactivity was determined from #-count. Results are expressed as % radioactivity per g 
organ relative to the total radioactivity injected. For recovery and survival determinations of 
radioactive platelets, blood samples were collected immediately (< 2 min), and at 0.5 h, 1 h 
and 24 h after platelet infusion and #-count determined [166]. 
 
Macrophage depletion.  
 
Mice were depleted of phagocytic cells by a single injection of liposomes containing 
dichloromethylene bisphosphonate (clodronate liposomes) [158, 167]. Mice were injected 
intravenously with 0.02 ml of clodronate liposomes per 10 g body weight 24 h prior to 
platelet transfusions. This treatment depletes 99% of Kupffer cells and 95% of splenic 
macrophages [158, 167]. Staining for macrophages was performed using an antibody to 
mouse F4/80 (SEROTEC) in tissue sections of clodronate treated and untreated mice. No 
F4/80 staining was detected following clodronate-liposome treatment. Control liposomes 
were prepared with PBS in place of clodronate (Fig. 9).  
 
 
 
 
Control liposomes  
injected 
Clodronate filled 
liposomes  injected 
>24 h mice lacking 
macrophages >24 h mice containing 
macrophages 
Fig. 9 
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Platelet clearance inhibition studies using asialofetuin and fetuin.  
A bolus of 10 mg asialofetuin or fetuin was injected via the retro-orbital venous plexus into 
WT C57/Bl6 mice 2 min before the platelet transfusion. Following platelet transfusion, 5 mg 
asialofetuin or fetuin was injected intravenously at time points of 10, 20, 30 and 60 min. The 
recipient animals were bled at 2, 10, 30, 90 min and the survival of labeled platelets 
determined by flow cytometry, as described above.  
 
In vitro platelet ingestion studies. 
 
In vitro HepG2 based platelet ingestion assay.  
 
We maintained human HepG2 hepatocarcinoma cells in "MEM (GIBCO Invotrigen), 2% 
heat-inactivated bovine calf serum (BCS), 3% standard fetal bovine serum (FBS), and 1% of 
a penicillin and streptomycin solution composed of 10,000 U ml
-1
 penicillin G and 10 mg ml
-
1
 streptomycin sulphate. HepG2 cells were not passaged > 2 times before use. For assays, the 
HepG2 cells were transferred to 24-well plates (10
6
 per well), allowed to adhere for 24 h, and 
starved for 30 min. 
 
Cytochalasin D (SIGMA) was diluted into "MEM media at the indicated concentrations and 
added to the HepG2 cells. DMSO was used as control. To study if the AMR mediated the 
ingestion of platelets in vitro, asialofetuin (competitive asialoglycoprotein receptor inhibitor) 
and fetuin (control) were diluted into "MEM media at 1, 10 or 100 #g/ml, respectively, and 
added to the HepG2 cells. 1x10
8
 CM-Orange-labelled platelets (fresh 22 °C platelets or 
platelets cooled at 0°C or 4 °C) were added per well, with or without cytochalasin D. 
Hepatocytes and platelets were incubated for 5-30 min at 37 °C with gentle agitation. After 
the incubation period, the HepG2 monolayers were washed 3 times by removing and 
changing the buffer. HepG2 cells were dissociated from the wells with 0.05% trypsin, 0.53 
CM-Orange labeled platelets 
were added 
to HepG2 cells  
Adherent 
platelets 
Ingested 
platelets 
Labeled platelets 
FL 2 
Adherent 
platelets 
Ingested 
platelets 
HepG2 cells were dissociated from 
wells. Adherent platelets were labeled 
with the FITC conjugated antibody to 
human CD61 
Fig. 10 
FL 1 CD61 
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mM EDTA in HBSS (GIBCO Invitrogen) at 37 °C for < 10 min. CM-Orange-labeled platelet 
ingestion was quantified by flow cytometry. HepG2 cells were gated according to their 
forward and side scatter characteristics. HepG2 with ingested platelets acquired orange 
fluorescence. Platelets adherent to HepG2 cells were labeled with the FITC conjugated 
antibody to human CD61 (Fig. 10). 
 
Studies of platelets surface glycoproteins involved in platelet-hepatocyte 
interaction.  
 
Removal of the extracellular domain of GPIb" .  
 
GPIb" was enzymatically cleaved from the surface of human or mouse platelets in platelet 
buffer containing 1 mM Ca
2+ 
and 10 #g ml
-1
 of the snake venom metalloprotease mocarhagin 
[168] or 10 #g ml
-1
 O-sialoglycoprotein endopeptidase, respectively (Fig. 3). After the 
enzymatic digestion, the platelets were washed by centrifugation, resuspended in platelet 
poor plasma (PPP), and allowed to rest for 30 min at 37 °C before storage at 4 °C.  The 
extent of GPIb" removal was monitored by flow cytometry using 5 #g ml-1 of the FITC-
conjugated antibody to human GPIb" (clone SZ2) or 5 #g ml-1 of the PE-conjugated 
antibody to mouse GPIb" (clone Xia.G5).   
 
 
Measurement of glycan exposure on platelet surfaces.  
 
Fresh 22 °C platelets or platelets stored in platelet buffer for 2 h at 0 °C, or in plasma for 48 h 
at 4 ºC, were diluted 4-fold with platelet buffer, collected by centrifugation at 830 x g for 5 
min, and resuspended in platelet buffer at 1x10
7 
ml
-1
. Surface galactose was analyzed by flow 
cytometry following incubation with FITC-conjugated RCA I or ECA at 0.1 and 10 #g ml
-1
, 
respectively. Surface !GlcNAc was measured by incubation with FITC-conjugated s-WGA 
at 0.1 #g ml
-1
. Samples were incubated at RT for 20 minutes and diluted 5-fold with platelet 
buffer before analysis by flow cytometry (Fig. 5). 
 
CM-orange WT 
platelets were 
transfused into 
ST3Gal-IV
–/– 
mice 
Flow cytometry  
FL1  
FL2  
Unlabeled 
platelets  
CM-orange 
platelets+vWf  
Unlabeled 
platelets+vWf  
Fig. 11 
vWf binding detected in PRP 
using
 
FITC-conjugated rabbit 
anti vWf antibody 
CM-orange 
platelets  
vWf antibody  
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Detection of bound vWf to transfused platelets.  
 
WT platelets were fluorescently labeled by incubation with 1.8
 
#M CM-Orange (Invitrogen) 
and transfused into WT or ST3Gal-IV
-/-
 mice. Blood samples were obtained immediately (1 
minute) after transfusion,
 
and vWf binding was measured in PRP by flow cytometry using 
FITC-conjugated rabbit anti-vWf antibody (Emfret). The percentage
 
of platelets positive for 
green and orange fluorescence was
 
determined (Fig. 11). 
 
Additional Materials and Methods used in PAPER I, II and III are published [119, 136, 
149].  
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DISCUSSION. 
 
The major focus of this thesis was to determine clearance mechanism for platelets stored at  
Fig. 12 Dual roles of lectin receptors in platelet clearance. The von Willebrand factor 
receptor (vWfR) complex, specifically GPIb!, has complete and incomplete N-linked glycans 
with exposed "GlcNAc and/or galactose residues. Upon short-term refrigeration, vWfRs and 
exposed "GlcNAc aggregate, initiating recognition and phagocytosis by the macrophage !M"2 
integrin. Extended refrigeration is followed by additional surface changes such as 
“hyperclustering” of receptors, galactose exposure, and binding of vWf with increased galactose 
exposure. Increase of galactose density on platelets induces platelet recognition by 
asialoglycoprotein receptors on hepatocytes (Ashwell-Morell receptors), which recruits 
clearance mechanisms in addition to macrophage depended platelet clearance through !M"2 
integrins. 
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4ºC for 48 hrs in plasma (long-term refrigerated platelets). Our results revealed an 
unexpected macrophage-independent clearance mechanism for sialic acid deficient platelets 
mediated by the Ashwell-Morell receptors on hepatocytes [150]. The mechanisms leading to 
clearance of short- and long-term refrigerated platelets are schematically depicted in Fig. 12. 
This observation, however, contradicts previously reported data that galactosylation of 
exposed !GlcNAc residues on short-term refrigerated platelets improves chilled platelet 
circulation [135]. The original finding that galactosylation rescued the circulation of short-
term cooled platelets was rationalized by the hypothesis that exposed "GlcNAc and "Gal 
only represent a minority of the exposed glycans on the surface of platelets, while the 
majority of the glycans are fully sialylated, which prevents the recognition of the platelets by 
different glycan receptor systems.  
 
The amount of immature carbohydrate exposure on the cell surface is critical in eliciting cell 
clearance by lectins [169]. Sequential transfusions of neuraminidase-treated rabbit platelets 
into rabbits have shown that >10% of the total platelet surface sialic acid must be removed to 
elicit recognition by the Asgpr system. In accordance with this notion, we show that exposure 
of galactose residues [169] increases with storage and refrigeration, although the mechanism 
of galactose exposure is unclear. It is possible that platelets release active sialidase that can 
cleave terminal sialic acid residues, revealing underlying galactose residues. Evidence that 
supports this mechanism is the increased binding of galactose-specific lectins to long-term 
refrigerated platelets but not to short-term refrigerated platelets. Glycans associated with 
GPIb" are the major targets of this activity as judged in platelet lysates and 
GPIb" immunoprecipitates from long-term refrigerated platelets. Platelets from ST3GalIV-/- 
mice have exposed galactose on surface glycoproteins because they lack "2-3-
sialyltransferase activity [143, 170]. However, the extent of galactose exposure on 
refrigerated platelets is less than that present on the surface of ST3GalIV
+/-
 platelets that 
retain their ability to circulate with normal lifetimes when transfused into WT mice [149], a 
finding that further substantiates the importance of glycan density and/or presentation for 
lectin recognition. The observed increase in protein clustering [136], and/or alterations in 
lipid-glycans following long-term refrigeration, may lead to changes in glycan presentation 
and density, thus amplifying the galactose signal and allowing recognition by Asgprs. 
Clustering of GPIb" subunits, as we observed in electron micrographs, increases the 
localized density of galactose or glycan presentation, which enhances lectin avidity and 
binding [136].  Clustering in the cold could be facilitated by cytoskeletal and membrane 
phase changes [171, 172].  It is possible that physiologically functional microdomains 
present at 37°C aggregate into macrodomains in human blood platelets as they chill below 
their membrane lipid phase transition temperatures [173, 174].  
 
Deficient sialylation of vWf increases vWf binding to platelets in vivo and in vitro [133, 140, 
146]. This suggests that increased binding of deficiently sialylated vWf to platelets may 
additionally contribute to the accelerated clearance of ST3Gal-IV
-/-
 platelets and long-term 
refrigerated platelets. Evidence for the hypothesis that desialylated vWf may contribute to 
platelet clearance comes from experiments that remove the 45 kDa GPIb" domain which 
binds to vWf. Removal of the 45 kDa domain restored the circulation of long-term 
refrigerated platelets and platelets derived from ST3GalIV
-/-
 mice. However, removal of the 
45 kDa GPIb" domain does not completely rescue the initial recovery of long-term 
refrigerated platelets, indicating that other factors influence the initial recovery [136]. 
Cleavage of the GPIb" by ADAM 17 causes a dramatic loss of platelet recovery following 
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transfusion [175].  Loss of GPIb" following refrigeration and rewarming could modulate the 
recoveries of long-term refrigerated platelets. It is therefore possible that desialylation or 
changes in glycan structure on other highly glycosylated proteins, such as "IIb!3, play a role 
in the recognition of both long-term refrigerated platelets and ST3GalIV deficient platelets. It 
remains to be determined if, during storage, platelets release active sialidases, thus affecting 
sialylation of plasma proteins, glycolipids or plasma proteins such as vWf, fibrinogen or 
fibronectin. This would affect platelet clearance.  
 
Macrophage versus hepatocyte mediated platelet clearance.  
 
Macrophages initially remove a large fraction of transfused platelets (~40%) [136], 
indicating their regulatory role in platelet recoveries. Although macrophages are widely 
regarded as the key phagocytes in regulating platelet clearance [176-178] [136], we have 
found that fresh platelets isolated from ST3GalIV deficient mice as well as long-term 
refrigerated and fresh room temperature platelets are cleared even in the absence of 
macrophages. Macrophage removal in mice somewhat improved platelet recoveries of 
ST3GalIV
-/- 
platelets and long-term refrigerated platelets. Platelets refrigerated for 48 h have 
exposed !GlcNAc residues [135]. Covering exposed !GlcNAc residues on long-term 
refrigerated platelets by galactosylation deprives the macrophage !2-integrin of its ligand, 
but promotes recognition by Asgprs. Macrophage depletion should therefore improve non-
galactosylated short-term cooled platelet survival but have no effect or decrease 
galactosylated platelet survival. Consistent with these predicted results, we show that non-
galactosylated platelet recoveries and survivals are significantly improved and recoveries of 
long-term refrigerated and galactosylated are further decreased in platelets of macrophage-
depleted mice. These results show that that the recoveries of both short-term and long-term 
cooled platelets are governed by !2-integrin lectins on macrophages. However, survivals of 
transfused platelets (independent of their pretreatment) remain unaffected by macrophage 
depletion, thus revealing a fine interplay between macrophage and hepatic lectin receptors in 
the removal of platelets. Taken together, these findings imply that platelet lifespan is defined 
by hepatocyte Ashwell-Morell receptors and that functional macrophages do not play a 
substantial role in determining platelet survival, but regulate platelet recoveries following 
platelet transfusion. Interestingly, macrophage depletion had the biggest impact on fresh 
room temperature platelet recoveries, which implies that “defining” platelet recovery, or the 
immediate clearance of a transfused platelet, may involve more than lectin-mediated 
mechanisms. However, we cannot exclude that a small portion of macrophages may still be 
present following clodronate treatment.  
 
Whether the hepatic-based system also functions to remove senile platelets at the end of their 
functional life remains to be established. In this case, platelets would lose sialic acid while 
circulating (aging), possibly due to release of endogenous sialidases. In addition, lifespan is 
limited by endogenous platelet apoptotic machinery [179] and scavenger receptors. 
Furthermore, some loss of platelets may also be attributed to platelets that function to ensure 
vascular integrity, i.e. bind to damaged vessels [180, 181]. How adherent platelet thrombi 
and debris are removed, if not by macrophages and hepatocytes, remains to be determined.  
 
Multiple hepatic clearance systems
 
contribute to varying extents in clearing soluble epithelial 
mucins that aberrantly enter
 
circulation. Receptors collaborating in the clearance of
 
human 
colon carcinoma mucins included the hepatocyte ASGPR (HL-I/II),
 
Kuppfer cell Gal-Rs 
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(MGL-1 and 2) and Man/GalNAc-4-SO4-R, endothelial
 
cell Man/GalNAc-4-SO4-R, 
hyaluronic acid receptor for endocytosis,
 
and SRs (SRAI/II, SRD, and SRBI). It appears that 
secretory mucins entering circulation are cleared before they can cause
 
pathologic events, 
such as those involving platelet and leukocyte
 
aggregation [182]. Whether or not such 
"complex" high-capacity
 
clearance mechanisms take place in the clearance of “pathologic 
platelets or platelets with pathologic glycan exposure” has yet to be determined.  
 
 Glycans in transfusion medicine.  
The 1930 Nobel Prize in Medicine was awarded to 
Karl Landsteiner “for his discovery of human 
blood groups” as the major cause of blood 
transfusion reactions.  The ABH blood group 
polymorphisms of humans and other primates is 
determined by expression of A, B or H (O) 
antigens of types 1-4, which are terminal neutral 
glycan sequences found in abundance on 
glycoproteins and glycolipids (Fig 13).  
Platelets, like red blood cells and other tissues 
[183], express
 
ABH antigens on a variety of 
membrane glycoproteins and
 
glycosphingolipids 
[184-186]. Clinically, transfusion of ABH-
incompatible
 
platelets can be associated with 
decreased recovery, [186, 187] shortened
 
survival 
[188], and an increased incidence and onset of 
HLA-immune
 
refractoriness[187, 189]. Platelet 
activation, including platelet refrigeration, causes 
structural changes in surface glycoproteins, altering 
the presentation of immature glycans on the 
platelet surface (unpublished observation). 
Incomplete glycans on activated platelets may induce clearance by lectins on phagocytic 
cells, including antigen-presenting cells, thereby facilitating immune responses leading to 
alloimmunization following repeated platelet transfusions.
 
On the other hand, “activated 
platelets” survive normally once transfused [67, 68] indicating that immature glycans may 
not always be recognized as “pathologic”. We did not test if long-term refrigerated platelets 
bind antibodies or if repeated long-term refrigerated platelet transfusions induce antibody 
production, a question that should be addressed in the future.  
 
The question remains: Can cooled platelets circulate? Glycans associated with GPIb! and 
vWf appear to be a major target of sialidase activity. Blocking sialidase activity during 
refrigeration of long-term stored platelets may be one of approach to prevent sialic acid loss 
and improve platelet circulation. Once the role and contribution of lectin receptors has been 
settled, future studies should also investigate if re-glycosylation, i.e. a combination of 
galactosylation and sialylation of immature platelet surface glycans, can rescue refrigerated 
platelet survival to accommodate their refrigeration for transfusion. The surprising presence 
of multiple glycosyltransferases (galactosyltransferases and sialyltransferases) in and on the 
surface of platelets may have implications for platelet functionality as suggested previously. 
Specific GPIb! glycans would be altered by specific sialidases and sialyltransferases leading 
Glucose
Galactose
Fucose
N-acetyl-D-
glucosamine
ABH antigens
A
B
H
Fig. 13 Schematic representation of 
ABH antigens. 
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to lectin-mediated clearance. It is possible that donor sugars and secreted 
glycosyltransferases regulate platelet function and survival per se. The specific role of 
neuraminidases and sialyltransferases in platelets needs to be addressed in the future.  
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CONCLUDING REMARKS. 
 
In an attempt to address the problem of why platelets stored at 4ºC do not circulate, forcing 
platelets to be stored at room temperature for transfusion, we identified novel and unexpected 
platelet mechanisms. Earlier work showed that the macrophage "M!2 integrin recognizes 
GPIb" associated !GlcNAc moieties following short-term refrigeration (2 h) in the absence of 
plasma, resulting in phagocytotic clearance of mice platelets in vivo. Galactosylation of 
!GlcNAc residues blocks the recognition of short-term refrigerated platelets by macrophage 
"M!2 and allows short-term refrigerated platelets to circulate in mice. However, 
galactosylation does not prevent the removal of human platelets refrigerated long-term in 
plasma. The aim of this thesis was to investigate the clearance mechanism of long-term 
refrigerated platelets in plasma.  
 
The major results of this thesis are: 
We developed a mouse model of platelet storage for 48 hours at 4°C and demonstrated that: 
 
I) UDP-galactose treatment of mouse platelets also did not prevent their rapid clearance 
in agreement with the human platelet study. These results suggested that exposed 
!GlcNAc residues were not the sole factor determining the clearance of long-term 
4ºC stored platelets in either mice or humans. This was confirmed by the rapid 
clearance of 48 h, 4ºC stored galactosylated mouse platelets in !M"2 integrin 
knockout mice.  
 
II) In vitro measured surface changes (P-selectin exposure, annexin V binding, von 
Willebrand factor binding) are comparable between mouse and human platelets stored 
in plasma for 48 h at 4ºC.  
 
III) Short-term cooling (2 h, 0°C) leads to !GlcNAc exposure, but not to an increased 
galactose exposure on mouse and human platelets. In contrast, storage of mouse and 
human platelets in plasma for % 48 h at 4°C leads to increase in galactose exposure.  
 
IV) Exposed galactose residues on platelets are recognized by galactose lectins, 
specifically by hepatic Asialoglycoprotein (Ashwell-Morell) receptors. These 
conclusions are based on the following evidence: 
 
a) Macrophage depletion in mice using clodronate encapsulated liposomes significantly 
improves the circulation of 2 h chilled and transfused platelets but does not prevent the 
clearance of 48 h refrigerated platelets;  
b) Immunohistology revealed abundant location of 48h-refrigerated platelets in liver 
hepatocytes;  
c) Binding of the !Gal-recognizing lectin RCA-I increases by ~1.5-fold following 48 h-
refrigeration; 
d) Mice lacking Asgr-1 or Asgr-2 subunits of the Asgr1/2 support 48 h-refrigerated platelet 
circulation times comparable to room temperature stored platelets;  
e) Co-injection of asialofetuin, a competitive inhibitor of asialoglycoprotein-receptors, 
restores the survival of 48 h-refrigerated platelets in wild type mice;  
f) The human hepatic cell line (HepG2 cells) ingest fluorescently labeled long-term 
refrigerated platelets in culture, and asialofetuin prevents this ingestion;  
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g) The glycosylated GPIb" N-terminal domain (the binding site for von Willebrand factor) 
on 48 h platelets is a major target for Ashwell-Morell receptor; 
h) Circulation of 48 h-refrigerated platelets is markedly improved by removal of GPIb"’s N-
terminal domain using O-sialoglycoprotein peptidase;  
i) Immunoblotting of long-term refrigerated platelets revealed that increased galactose 
exposure is associated with GPIb"'s N-terminus and a protein of the same molecular weight 
as vWf as defined using an antibody specific for vWf. 
 
V) Using mice lacking sialyltransferase ST3GalIV-/- we determined that clearance of 
platelets with increased galactose exposure is also mediated by asialoglycoprotein 
receptors on hepatocytes and macrophages. These conclusions are based on the 
following evidence:!!! !!!! !! 
 
a) Platelets from ST3Gal-IV
-/- 
have increased exposure of !Gal residues on their surface, as 
detected by immunoblotting and flow cytometry using peroxidase or FITC labeled RCA I 
lectin; 
b) Immunohistology staining revealed ST3Gal-IV
-/-
 platelets in both hepatocytes and 
macrophages; 
c) Macrophage depletion in WT mice improved transfused ST3Gal-IV
-/-
 platelet recoveries 
and survivals; 
d) Co-injection of asialofetuin, a competitive inhibitor of asialoglycoprotein-receptors, 
restores the survival of ST3Gal-IV
-/-
 platelets in WT mice;  
f) HepG2 cells ingest platelets ST3Gal-IV
-/-
 in culture, and asialofetuin prevents this 
ingestion; 
g) The glycosylated N-terminal domain of GPIb", the binding site for vWf on ST3Gal-IV-/-, 
is a major target for asialoglycoprotein receptors; 
h) The circulation of ST3Gal-IV
-/- 
platelets is markedly improved by removal of GPIb"’s N-
terminal domain using O-sialoglycoprotein peptidase, pointing to the fact that increased 
galactose exposure on the surface of ST3Gal-IV
-/-
 platelet is associated with of GPIb" and 
vWf; 
i) WT mice have increased binding to vWf with sialic acid deficiency in vivo and cleared 
faster upon transfusion. 
 
 Using two mouse platelet models with exposed !Gal residues we have shown that clearance 
of desialylated platelets is mediated by asialoglycoprotein receptors on hepatocytes and to 
some extent macrophages for ST3GalIV deficient platelets. These results demonstrate a 
totally unexpected platelet-carbohydrate and lectin based clearance mechanism. It is likely 
that additional lectin receptors are involved in platelet clearance. It is important to determine 
if the demonstrated hepatic platelet clearance systems also contribute to “senescent platelet 
clearance” and to understand why hepatocytes ingest desialylated platelets. 
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